Related Experiment Video
Updated: Jul 21, 2026
07:59
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Enzymatically mediated engineering of multivalent MHC class II-peptide chimeras
S Casares1, C A Bona, T D Brumeanu
1Department of Microbiology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA.
Protein Engineering
|May 9, 2001
Summary
Researchers developed a new enzymatic method to create multivalent major histocompatibility complex (MHC) class II-peptide ligands. These engineered ligands demonstrate enhanced stability and potent T-cell modulation for potential therapeutic applications.
Area of Science:
- Immunology
- Biotechnology
- Molecular Engineering
Background:
- Soluble, bivalent major histocompatibility complex (MHC) class II-peptide ligands for T-cell receptor (TCR) were previously engineered.
- Increased ligand valence correlates with higher avidity for TCRs and enhanced T-cell stimulation potency.
- Existing ligands exhibit immunomodulatory effects in vitro and in vivo.
Purpose of the Study:
- To develop a novel enzymatic method for increasing the valence of MHC-peptide ligands.
- To generate and characterize covalently stabilized tetravalent and octavalent MHC II-peptide ligands.
- To investigate the immunomodulatory effects of these multivalent ligands on antigen-specific CD4(+) T-cells.
Main Methods:
- Enzymatic cross-linking of N-glycan moieties on dimeric MHC II-peptide units.
- Utilized a flexible, bifunctional polyethylene glycol linker for cross-linking.
- Generated covalently stabilized tetravalent and octavalent MHC II-peptide ligands.
Main Results:
- Successfully created multivalent MHC II-peptide ligands with enhanced stability.
- Ligands maintained structural integrity in blood and lymphoid organs for up to 72 hours.
- Multivalent ligands demonstrated efficient polarization of CD4(+) T-cells towards type 2 differentiation or induced T-cell anergy and apoptosis, depending on TCR/CD4 clustering.
Conclusions:
- Enzymatic engineering provides a rational approach to create multivalent MHC-peptide ligands.
- These multivalent ligands exhibit potent and tunable modulatory effects on antigen-specific T-cells.
- This strategy holds promise for developing novel therapeutic agents targeting T-cell responses.
Related Concept Videos
01:26Antigens Involved in Adaptive Immunity
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
01:31Antigen Processing Pathways
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
MHC Class I: Presenting Endogenous...